Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1316 plus SHR-8068 and platinum-based doublet chemotherapy as first-line treatment in advanced non-squamous NSCLC with STK11/KEAP1/KRAS mutations
CTR20240806Phase 3Active
- Sponsor
- Chengdu Shengdi
- Start
- May 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of adebrelimab in non-small cell lung cancer (NSCLC), sponsored by Chengdu Shengdi. Started May 2024; status: active.
02
Drugs
adebrelimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20240806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240806.